- Home
- PETS vs ABVC Comparison
PETS vs ABVC Comparison
Compare PETS & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ABVC
- Stock Information
- Founded
- PETS 1996
- ABVC 2015
- Country
- PETS United States
- ABVC United States
- Employees
- PETS N/A
- ABVC N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ABVC Health Care
- Exchange
- PETS Nasdaq
- ABVC Nasdaq
- Market Cap
- PETS 58.9M
- ABVC 52.1M
- IPO Year
- PETS N/A
- ABVC N/A
- Fundamental
- Price
- PETS $2.82
- ABVC $2.84
- Analyst Decision
- PETS Sell
- ABVC
- Analyst Count
- PETS 1
- ABVC 0
- Target Price
- PETS $3.20
- ABVC N/A
- AVG Volume (30 Days)
- PETS 92.2K
- ABVC 89.5K
- Earning Date
- PETS 11-05-2025
- ABVC 11-13-2025
- Dividend Yield
- PETS N/A
- ABVC N/A
- EPS Growth
- PETS N/A
- ABVC N/A
- EPS
- PETS 0.02
- ABVC N/A
- Revenue
- PETS $247,010,000.00
- ABVC $391,242.00
- Revenue This Year
- PETS N/A
- ABVC $735.18
- Revenue Next Year
- PETS N/A
- ABVC N/A
- P/E Ratio
- PETS $164.97
- ABVC N/A
- Revenue Growth
- PETS N/A
- ABVC 186.84
- 52 Week Low
- PETS $2.72
- ABVC $0.40
- 52 Week High
- PETS $6.85
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- PETS 50.01
- ABVC 51.31
- Support Level
- PETS N/A
- ABVC N/A
- Resistance Level
- PETS $3.08
- ABVC $2.86
- Average True Range (ATR)
- PETS 0.10
- ABVC 0.15
- MACD
- PETS -0.12
- ABVC -0.10
- Stochastic Oscillator
- PETS 88.68
- ABVC 90.47
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.